Tango Therapeutics, Inc. (TNGX): Revenue
$62.38M
Year ended 2025-12-31
$53.81M
Trailing 12 months to 2026-06-30
+35.9%
3-year compound annual growth
+52.1%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.38M | +48.3% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $42.07M | +15.2% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $36.53M | +46.9% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $24.86M | -32.9% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $37.04M | +383.8% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $7.66M | n/a | 2022-03-28, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $62.38M | +48.3% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $62.90M | +699.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $63.26M | +9.7% |
| Journey Medical Corp (DERM) | 2025-12-31 | $61.24M | +11.1% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $65.32M | -3.4% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $66.80M | +39.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $67.48M | +25.2% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $57.57M | -13.3% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $69.26M | -31.8% |
Compare TNGX, NUVB, FBIO, DERM side by side · Screen every company in Pharmaceutical Preparations ↗